INDGN Indegene Q3 FY25 results (Oct–Dec 2024) and concall
Indegene reported a resilient Q3 FY25 with steady sequential revenue growth and significant margin expansion. The company is benefiting from a 'cautious recovery' in the biopharma industry, with strong renewal rates and a robust pipeline of mid-tier clients. Management is successfully leveraging GenAI and automation to offset wage hikes and improve revenue per employee, even as total headcount sees a strategic shift toward domain-heavy roles.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 |
|---|---|---|
| Revenue | 282 | 287 |
| EBITDA | 46 | 52 |
| Net profit | 45 | 50 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
